A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
← catalyst calendarNCT06701513 · readout in 620 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
350estimated
Sites
48
Countries
France, Switzerland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-29 | actual | When the study began enrolling |
| Primary completion | 2028-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Psoriasis
Intervention
- Drug: Deucravacitinib
Primary outcomes
what the primary-completion date above is the date OFPhysician's Global Assessment (PGA) 0/1 response
measured Baseline and at months 4, 12, 18 (optional), and 24
Dermatology Life Quality Index (DLQI) 0/1 response
measured Baseline and at months 4, 12, 18 (optional), and 24
Time from date of treatment initiation to date of discontinuation
measured Up to 24 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed